IBL 101
Alternative Names: IBL-101Latest Information Update: 24 Aug 2023
At a glance
- Originator Spanish National Cancer Research Centre
- Developer Inflection Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules; Urologics
- Mechanism of Action PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Lupus nephritis; Psoriasis; Rheumatoid arthritis